Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.

@article{Saitoh2007EfavirenzPI,
  title={Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.},
  author={Akihiko Saitoh and Courtney V Fletcher and Richard Brundage and Carmelita G Alvero and Terrence Fenton and Karen Hsia and Stephen A Spector},
  journal={Journal of acquired immune deficiency syndromes},
  year={2007},
  volume={45 3},
  pages={280-5}
}
BACKGROUND The CYP2B6-G516T polymorphism has been shown to alter plasma efavirenz (EFV) concentrations in adults. The impact of CYP2B6-G516T polymorphisms on EFV concentrations may be different in children because of differences in liver maturation and drug dosage. METHODS The CYP2B6-G516T polymorphisms were analyzed in 71 HIV-1-infected children receiving highly active antiretroviral therapy (HAART) containing EFV for >or=6 months. EFV pharmacokinetics, toxicity profiles, and viral… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Similar Papers

Loading similar papers…